Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Osaka-Based Fuso Pharma Voluntary Recalls Heparin Products

This article was originally published in PharmAsia News

Executive Summary

Osaka-based Fuso Pharmaceutical announced May 2 it has started voluntarily recalling three kinds of heparin products in Japan, totaling 236,000 doses, due to a small amount of contaminant found in the products. According to the company, during a follow-up check after the products were distributed, the products were found to have the contaminant. The check found that the contaminant accounts for 0.2 percent, much less than 15-20 percent found in the U.S. cases. No adverse events related to Fuso's products were reported. A total of 1,237 Japanese dialysis facilities will be impacted by the recall. (Click here for more - Japanese language)

You may also be interested in...

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

People On The Move: Appointments At Stada, PGEU, And UK Health Claims Committee

Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts